BioLamina
Agent21Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Trust90Data Trust: 90/100. Top 25%. Measured by StartupHub.ai. Median 61.Developing and manufacturing laminin-based cell culture substrates for advanced cell therapies and drug discovery.
About
BioLamina is a Stockholm-based biotech scale-up specializing in matrix biology and cell culture. Founded in 2009, the company develops and manufactures high-quality, chemically defined, and animal-origin-free human recombinant laminin-based cell culture substrates. These substrates are designed to enable the reliable growth and differentiation of pluripotent stem cells and other primary cells, which are crucial for advancing cell therapies for serious chronic diseases and enhancing the precision of cell-based models in drug discovery and development.
Listed competitors
Global supplier of life science research tools, including antibodies, reagents, and assays.
Integrated life science company specializing in diagnostic testing solutions and life science raw materials.
Develops and markets bioproduction tools for cell and gene therapy manufacturing and distribution.
Also in this space
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Life Sciences
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Life Sciences
A vertically-integrated procurement platform for the life sciences industry.
Shares Biotechnology, Life Sciences
A global leader in clinical pharmacology and bioanalytical sciences.
Shares Biotechnology, Life Sciences
Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.
Shares Biotechnology, Biotech
Automated wet lab for AI-driven protein design, enabling rapid synthesis, expression, and testing of thousands of protein designs.
Shares Biotechnology, Drug Discovery
Key facts
- Website
- biolamina.com
- Headquarters
- Stockholm, Sweden
- Founded
- 2009
- Total funding
- $41M (Venture Debt)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Apr 2026 | Venture Debt | $20M | European Investment Bank (EIB) |
| 12 Sept 2023 | Series B | $18M | Lauxera Partners |
| 13 Nov 2013 | Later Stage VC | $2M |
Tech stack
Detected on biolamina.com, last scanned 18 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4, Google Tag Manager
- SEO
- Yoast SEO
- Support
- HubSpot
- CMS / Builders
- WordPress
- Email provider
- Microsoft 365
BioLamina scores 39. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
What does BioLamina do?
BioLamina's products, such as Biolaminin® substrates, are used in cell therapy development, including clinical trials.
Is BioLamina trustworthy and reputable?
StartupHub's Data Trust & Reputation score for BioLamina is 90 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has BioLamina raised?
BioLamina has raised a total of $41M in funding. The most recent round on record is Venture Debt.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for BioLamina
